RT期刊文章SR电子T1 Macitentan肺动脉高压由于左心室功能障碍摩根富林明欧洲呼吸杂志乔和J FD欧元欧洲呼吸学会SP 1701886 10.1183/13993003.01886 -2017签证官51 2 A1 Vachiery, jean - luc A1 Delcroix,马里昂A1 Al-Hiti,希188bet官网地址克A1 Efficace, Michela A1 Hutyra,Martin A1 Lack, Gabriela A1 Papadakis, Kelly A1 Rubin，路易斯·j·年2018 UL //www.qdcxjkg.com/content/51/2/1701886.abstract AB MELODY-1研究评估macitentan肺动脉高压,因为左心脏病患者(PH-LHD)结合后和pre-capillary PH.63 PH-LHD患者和舒张压梯度≥7毫米汞柱和肺血管阻力(PVR) > 3随机分为马西坦10mg组(n=31)或安慰剂组(n=32)，为期12周。主要终点评估了纽约心脏协会功能分级从基线到治疗结束的显著液体潴留(由于液体超载或肠外利尿剂给药导致体重增加≥5%或≥5 kg)或恶化的复合因素。探索终点包括第12周n端脑利钠肽前体(NT-proBNP)和血流动力学的变化。7例马吉坦治疗组和4例安慰剂治疗组患者出现明显的液体潴留/功能等级恶化;治疗差异10.08% (95% CI−15.07-33.26;p = 0.34)。在第一个月，由液体保留成分驱动的差异是明显的。 At week 12, versus placebo, the macitentan group showed no change in PVR, mean right atrial pressure or pulmonary arterial wedge pressure; a non-significant increase in cardiac index (treatment effect 0.4 (95% CI 0.1–0.7) L·min−1·m−2) and decrease in NT-proBNP (0.77 (0.55–1.08)) was observed. Adverse events and serious adverse events were numerically more frequent with macitentan versus placebo.Macitentan-treated patients were quantitatively more likely to experience significant fluid retention versus placebo. Macitentan resulted in no significant changes in any exploratory end-points.In combined post- and pre-capillary PH patients, macitentan was associated with increased incidence of significant fluid retention versus placebo http://ow.ly/leop30hBkQm